Baracos, et al., “Stimulation of Muscle Protein Degradation and Prostaglandin E2 Release by Leukocytic Pyrogen (Interleukin-1)”, The New England Journal of Medicine, vol. 308, p. 553 (1983). |
Berge et al., “Pharmaceutical Salts”, Journal of Pharmaceutical Sciences, vol. 66, No. 1, pp. 1-19(1977). |
Beutler et al., “Recombinant Interleukin 1 Suppresses Lipoprotein Lipase Activity in 3T3-L1 Cells”, Journal of Immunology, vol. 135, pp. 3969-3971 (1985). |
Brahn et al., “Effect of Tumor Necrosis Factor Alpha (TNF-α) on Collagen Arthritis”, Lymphokine and Cytokine Research, vol. 11, pp. 253-256 (1992). |
Brunner et al., “Synthesis and antitumor activity of platinum (II) complexes containing substituted ethylenediamine ligands”, Eur. J. Med. Chem., vol. 25, pp. 35-44 (1990). |
Bundgaard et al., “A Novel Solution-Stable, Water-Soluble Prodrug Type for Drugs Containing a Hydroxyl or an NH-Acidic Group”, J. Med. Chem., vol. 32, pp. 2503-2507 (1989). |
Chandrasekhar et al., “Arthritis Induced by Interleukin-1 is Dependent on the Site and Frequency of Intraarticular Injection”, Clinical Immunology and Immunopathology, vol. 55, pp. 382-400 (1990). |
Clouse et al., “Monokine Regulation of Human Immunodeficiency Virus-1 Expression in a Chronically Infected Human T Cell Clone”, Journal of Immunology, vol. 142 pp. 431-438 (1989). |
Colbry et al., Synthesis and Antimalarial Properties of 2,4-Diamino-6[(aryl)thio, sulfinyl, and sulfonyl]pyrido[3,2-d]pyrimidines [1,2], J. Heterocyclic Chem., vol. 21, pp. 1521-1525 (1984). |
Cooper et al., “Acceleration of onset of collagen-induced arthritis by intra-articular injection of tumour necrosis factor or Transforming growth factor-beta”, Clin. Exp. Immunol., vol. 89, pp. 244-250 (1992). |
Courtenay et al., “Immunisation against heterologous type II collagen induces arthritis in mice”, Nature, vol. 283, pp. 666-668 (1980). |
Davies et al., “Asymmetric Syntheses of β-Phenylalanine, α-Methyl-β-phenylalanines and Derivatives”, J. Chem. Soc., Chem. Commun., pp. 1153-1155 (1993). |
Dinarello, “The Biological Properties of Interleukin-1”, Eur. Cytokine Netw., vol. 5, pp. 517-531 (1994). |
Dornow et al., “Über die Reduktion substituierter Cyanessigsäure-äthylester”, Chem. Ber 87, pp. 985-990 (1954). |
Firestein et al., “Stromelysin and Tissue Inhibitor of Metalloproteinases Gene Expression in Rheumatoid Arthritis Synovium”, American Journal of Pathology, vol. 140, pp. 1309-1314 (1992). |
Folks et al., “Susceptibility of Normal Human Lymphocytes to Infection with HTLV-III/LAV”, Journal of Immunology, vol. 136, pp. 4049-4053 (1986). |
Freifelder et al., “Synthesis of Primary 1,2-Diamines by Hydrogenation of α-Aminonitriles”, J. Am. Chem. Soc., vol. 82, pp. 696-698 (1959). |
Grussenmeyer et al., “Complexes of polyoma virus medium T antigen and cellular proteins”, PNAS USA, vol. 82, pp. 7952-7954 (1985). |
Kaiser, “Lateral Metallation of Methylated Nitrogenous Heterocycles” Tetrahedron, vol. 39, pp. 2055-2064 (1983). |
Kojima et al., “Preparation and Spectroscopic Studies of Steroisomers of the Tris[(S)-1-phenyl-1, 3-propanediamine]cobalt(III) Complex”, Bull. Chem. Soc. Jpn., vol. 55, pp. 1454-1459 (1982). |
Lahdevirta et al., “Elevated Levels of Circulating Cachectin/Tumor Necrosis Factor in Patients with Acquired Immunodeficiency Syndrome”, The American Journal of Medicine, vol. 85, pp. 289-291 (1988). |
Lang et al., “Tumor Necrosis Factor Impairs Insulin Action on Peripheral Glucose Disposal and Hepatic Glucose Output”, Endocrinology, vol. 130, pp. 43-52 (1992). |
Liu et al., “Tumor Necrosis Factor-α Expression in Ischemic Neurons”, Stroke, vol. 25, pp. 1481-1488 (1994). |
Maini et al., “Monoclonal anit-TNFα Antibody as a Probe of Pathogenesis and Therapy of Rheumatoid Disease”, Immunological Reviews, vol. 144, pp. 195-223 (1995). |
Matsumoto et al., “Synthesis of Fluorinated pyridines by the Balz-Schiemann Reaction. An Alternative Route to Enoxacin, A New Antibacterial Pyridonecarboxylic Acid [1]”, J. Heterocyclic Chem., vol. 21, pp. 673-679 (1984). |
Nishigaki et al., “Synthesis of 1-Substituted 1,4-Dihydro-7-[2-(5-nitro-2-furyl)vinyl]-4-oxo-1,8-naphthyridine Derivatives”, Chem. Pharm. Bull, vol. 17:9, pp. 1827-1831 (1969). |
Shohami et al., “Closed Head Injury Triggers Early Production of TNFα and IL-6 by Brain Tissue”, J. Cereb. Blood Flow Metab., vol. 14, No. 4, pp. 615-619 (1994). |
Svensson et al., “The Design and Bioactivation of Presystemically Stable Prodrugs”, Drug Metabolism Reviews, vol. 19(2), pp. 165-194 (1988). |
Swingle, “Evaluation for Antiinflammatory Activity”, Antiinflammatory Agents, Edited by Robert Scherrer and Michael Whitehouse, vol. II, Ch. 2, pp. 33-122 (1974). |
Szalkowski et al., “Antidiabetic Thiazolidinediones Block the Inhibitory Effect of Tumor Necrosis Factor-60 on Differentiation, Insulin-Stimulated Glucose Uptake, and Gene Expression in 3T3-L1 Cells”, Endrocrinology, vol. 136, pp. 1474-1481 (1995). |
Trentham et al., “Autoimmunity to Type II Collagen: An Experimental Model of Arthritis”, Journal of Experimental Medicine, vol. 146, pp. 857-868 (1977). |
Wheeler et al., “A Chiral Synthesis of Dapoxetine Hydrochloride, A Serotonin Re-uptake Inhibitor, and its 14C Isotopomer”, Journal of Labelled Compounds and Radiopharmaceuticals, vol. XXXI, No. 4, pp. 305-315 (1992). |
Williams et al., “Both p21ras and pp60v-src are required, but neither alone is sufficient, to activate the Raf-1 kinase”, PNAS USA, vol. 89, pp. 2922-2926 (1992). |
Winter et al., “Carrageenin-Induced Edema in Hind Paw of the Rat as an Assay for Antiinflammatory Drugs”, Proc. Soc. Exp. Biol. Med., vol. 111, pp. 544-547 (1962). |
Liu et al., “Cytokine-induced neutrophil chemoattractant mRNA expressed in cerebral ischemia”, Neuroscience Letters, vol. 164, pp. 125-128 (1993). |
Lee et al., “Low-Molecular-Weight TNF Biosynthesis Inhibitors: Strategies and Prospectives”, Circulatory Shock, vol. 44, pp. 97-103 (1995). |
Beyaert et al., “The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis in response to tumour necrosis factor”, EMBO Journal, vol. 15, pp. 1914-1923 (1996). |
Joosten et al., “Anticytokine Treatment of Established Type II Collagen-Induced Arthritis in DBA/1 Mice”, Arthritis & Rheumatism, vol. 39, pp. 797-809 (1996). |
Delarge, J. “A propos de quelques derives de la pyridine disubstituee-2,5”, Farmaco-Ed. Sc., vol. 29, pp. 101-108 (1974). |